SCHEMBL203558

SCHEMBL203558

CCOc1ccc(-c2ccc(C(=O)NC(C(=O)OC)C(F)(F)F)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.54
GAA P10253 2/20 0.54
TAS1R3 Q7RTX0 2/20 0.53
TAS1R1 Q7RTX1 2/20 0.53
NPSR1 Q6W5P4 2/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
PLK1 P53350 1/20 0.50
HPGD P15428 1/20 0.48
POLB P06746 1/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
HRH3 Q9Y5N1 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
F2 P00734 1/20 0.44
F10 P00742 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201274 0.86 TAS1R3 (0.52) RAB9AGAATAS1R3TAS1R1NPSR1
SCHEMBL202434 0.82 TAS1R3 (0.57) RAB9AGAATAS1R3TAS1R1KMT2A
SCHEMBL201903 0.80 ANPEP (0.41) GAATAS1R3TAS1R1ALDH1A1
SCHEMBL200965 0.78 HDAC1 (0.43)
SCHEMBL13366177 0.76 RAB9A (0.50) RAB9AGAATAS1R3TAS1R1NPSR1
SCHEMBL13366229 0.76 TAS1R3 (0.51) RAB9ATAS1R3TAS1R1NPSR1KMT2A
SCHEMBL19402619 0.75 PLK1 (0.69) RAB9AGAATAS1R3TAS1R1NPSR1
SCHEMBL10294829 0.75 NPSR1 (0.72) RAB9AGAATAS1R3TAS1R1NPSR1
SCHEMBL13366139 0.74 NPSR1 (0.56) RAB9AGAATAS1R3TAS1R1NPSR1
SCHEMBL4291553 0.74 RAB9A (0.69) RAB9AGAATAS1R3TAS1R1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 RAB9A 940/4885GAA 877/4885TAS1R3 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.